TL;DR
This study investigates the prognostic significance of genetic and expression alterations of two genes, LANCL2 and EGFR, in glioblastoma (GBM), the most aggressive form of brain cancer. The researchers found that amplification of these genes is common in GBM and that LANCL2 amplification, particularly in younger patients, is a significant predictor of overall survival.
What Problem Does This Paper Address?
Glioblastoma (GBM) is a devastating brain cancer with a poor prognosis, characterized by rapid growth and resistance to treatment. Identifying reliable biomarkers to predict patient outcomes is crucial for developing targeted therapies and improving patient care. While Epidermal Growth Factor Receptor (EGFR) has been extensively studied in GBM, the role of Lanthionine Synthetase C-like 2 (LANCL2), which is located in the same amplified genomic region as EGFR, has been less clear. This paper aims to clarify the prognostic value of both copy number variations (CNVs), mRNA, and protein expression of LANCL2 and EGFR, both individually and in combination, in GBM patients.
Methods
The researchers employed a multi-pronged approach to analyze the data:
- TCGA Database Analysis: They utilized data from The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas, a large public repository of cancer genomics and clinical data. This allowed them to analyze copy number variations (CNVs) and mRNA expression in a substantial cohort of GBM patients.
- Tumor Bank Analysis: To validate their findings, they also analyzed samples from a smaller cohort of 100 GBM patients from local tumor banks (Shenzhen Second People's Hospital and Sun Yat-sen University Cancer Center).
- Copy Number Variation (CNV) Assay: TaqMan Copy Number Assays were used to quantify the copy numbers of LANCL2 and EGFR genes in the tumor samples.
- Western Blotting: This technique was used to assess the protein expression levels of LANCL2 and EGFR.
- Immunohistochemistry (IHC): IHC was employed to visualize the protein expression and intracellular localization of LANCL2 and EGFR in tumor tissues, allowing for correlation with tumor grade.
- Statistical Analysis: A range of statistical methods were used, including Kaplan-Meier survival analysis, log-rank tests, chi-square tests, and Cox proportional hazards regression models for univariate and multivariate analyses to determine prognostic significance.
Datasets
- TCGA Pan-Cancer Atlas: This dataset provided genomic and clinical data for over 11,000 human tumors across 33 cancer types, with a specific focus on glioblastoma (GBM) and lower-grade gliomas (LGG).
- Tumor Banks: Samples from 100 GBM patients from the Shenzhen Second People's Hospital and Sun Yat-sen University Cancer Center were used for validation.
Key Insights and Ideas
- Co-amplification is Common: LANCL2 and EGFR genes are frequently amplified together in GBM, suggesting a shared genomic vulnerability in this cancer.
- LANCL2 Amplification as a Prognostic Factor: While EGFR amplification's prognostic role has been debated, this study highlights LANCL2 amplification as a significant predictor of poorer overall survival, especially in younger GBM patients. This suggests LANCL2 might be a more critical driver in certain GBM subsets.
- Age Matters: The prognostic impact of LANCL2 amplification appears to be age-dependent, with younger patients benefiting from this insight more than older patients.
- mRNA vs. Protein Expression: While both mRNA and protein overexpression of LANCL2 and EGFR were observed, only mRNA expression showed a positive correlation with gene amplification. Importantly, neither mRNA nor protein overexpression directly correlated with overall survival, suggesting that genetic alterations (amplification) might be more impactful for prognosis than expression levels alone in this context.
- LANCL2's Role in Recurrence: Protein expression of LANCL2 was found to be elevated in relapsing GBM compared to newly diagnosed GBM, hinting at its potential involvement in tumor recurrence.
- Intracellular Localization and Grade: The intracellular localization of LANCL2, but not EGFR, was found to correlate with the grade of gliomas, with higher grades showing nuclear and cytoplasmic localization. This suggests a potential functional shift of LANCL2 with tumor progression.
Key Results
- Amplification Frequencies: LANCL2 and EGFR amplification were found in approximately 27.65% and 44.35% of GBM patients in the TCGA database, respectively. In the tumor banks, these frequencies were even higher (62% for LANCL2 and 55% for EGFR).
- Co-amplification: Co-amplification of LANCL2 and EGFR was observed in 61.96% of GBM samples with LANCL2 amplification in the TCGA database and 47% of total GBM samples in the tumor banks.
- Prognostic Significance:
- In younger GBM patients (<60 years) from the TCGA database, LANCL2 amplification was a significant independent prognostic factor for overall survival (p=0.043, HR=1.657).
- This finding was validated in the tumor banks, where LANCL2 amplification was also a significant prognostic factor for OS in younger GBM patients (p=0.018, HR=2.199).
- However, LANCL2 or EGFR amplification, and their co-amplification, did not show a significant impact on OS in older patients (≥60 years) or IDH1/2-wild-type GBM patients.
- mRNA and Protein Expression: mRNA expression of LANCL2 and EGFR was positively correlated. However, neither mRNA nor protein overexpression of these genes was significantly correlated with overall survival.
Limitations and Future Work
- Sample Size: While the TCGA dataset is large, the tumor bank cohort is smaller, which might limit the statistical power for some analyses.
- Interaction Effects: The study acknowledges that interaction effects between variables like age, gender, and genetic status might influence OS, making it challenging to isolate the independent prognostic value of LANCL2/EGFR amplification in some cohorts.
- EGFRvIII and Other Variants: The study primarily focused on gene amplification and expression. Further investigation into the role of specific EGFR variants (like EGFRvIII) and other molecular alterations could provide a more comprehensive understanding.
- Functional Studies: While the study identifies prognostic associations, further functional studies are needed to elucidate the precise biological mechanisms by which LANCL2 influences GBM progression and recurrence. The observed correlation between LANCL2's intracellular localization and glioma grade suggests a promising avenue for future research.
- Therapeutic Targeting: The identification of LANCL2 as a potential prognostic marker, especially in younger patients, opens doors for exploring LANCL2 as a therapeutic target.
Summary updated